List of Vizimpro drug patents
Vizimpro is owned by Pfizer.
Vizimpro contains Dacomitinib.
Vizimpro has a total of 4 drug patents out of which 0 drug patents have expired.
Vizimpro was authorised for market use on 27 September, 2018.
Vizimpro is available in tablet;oral dosage forms.
Vizimpro can be used as first-line treatment of metastatic non small-cell lung cancer (nsclc) with egfr exon 19 deletions or exon 21 (l858r) substitution mutations as detected by an fda-approved test, administering daily a unit dosage of an irreversible egfr inhibitor covalently binding as claimed for 1st line treatment of gefitinib or erlotinib resistant metastatic nsclc with egfr exon 19 deletion or exon 21 l858r substitution with t790m mutation, administering daily a unit dosage of an irreversible egfr inhibitor covalently binding as claimed for 1st line treatment of gefitinib of erlotinib resistant metastatic nsclc with egfr exon 19 deletion or exon 21 l858r substitution.
Drug patent challenges can be filed against Vizimpro from 2022-09-27.
The generics of Vizimpro are possible to be released after 26 August, 2028.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7772243 | PFIZER | 4-phenylamino-quinazolin-6-yl-amides |
Aug, 2028
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8623883 | PFIZER | 4-phenylamino-quinazolin-6-yl-amides |
May, 2025
(2 years from now) | |
| US10603314 | PFIZER | Method for treating gefitinib resistant cancer |
Feb, 2026
(2 years from now) | |
| US10596162 | PFIZER | Method for treating gefitinib resistant cancer |
Feb, 2026
(2 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Sep 27, 2025 |
| New Chemical Entity Exclusivity (NCE) | Sep 27, 2023 |
Drugs and Companies using DACOMITINIB ingredient
NCE-1 date: 2022-09-27
Market Authorisation Date: 27 September, 2018
Treatment: First-line treatment of metastatic non small-cell lung cancer (nsclc) with egfr exon 19 deletions or exon 21 (l858r) substitution mutations as detected by an fda-approved test; Administering daily a unit dosage of an irreversible egfr inhibitor covalently binding as claimed for 1st line treatment of gefitinib of erlotinib resistant metastatic nsclc with egfr exon 19 deletion or exon 21 l858r substitution; Administering daily a unit dosage of an irreversible egfr inhibitor covalently binding as claimed for 1st line treatment of gefitinib or erlotinib resistant metastatic nsclc with egfr exon 19 deletion or exon 21 l858r substitution with t790m mutation
Dosage: TABLET;ORAL
VIZIMPRO family patents
10
United States
8
China
3
Norway
3
Korea, Republic of
3
Japan
3
Israel
2
Portugal
2
Russia
2
Spain
2
Brazil
2
New Zealand
2
Austria
2
Mexico
2
Hong Kong
2
Nicaragua
2
South Africa
2
Canada
2
Cyprus
2
Luxembourg
2
Slovenia
2
Hungary
2
Poland
2
Australia
2
Denmark
2
European Union
1
Germany
1
Malaysia
1
Uruguay
1
Panama
1
Guatemala
1
Croatia
1
Costa Rica
1
IB
1
AP
1
Argentina
1
Morocco
1
Peru
1
Taiwan, Province of China
1
Honduras
1
Tunisia
1
EA
1
Lithuania
1
ME
1
Ukraine
1
Georgia
1
Ecuador
1
RS
1
Netherlands
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic